NASDAQ:PACB - Pacific Biosciences of California Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pacific Biosciences of California Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.80 -0.09 (-1.84 %) (As of 01/28/2020 02:19 PM ET) Add Compare Today's Range$4.76Now: $4.80▼$4.9050-Day Range$4.64MA: $5.12▼$5.5852-Week Range$4.37Now: $4.80▼$7.50Volume36,912 shsAverage Volume2.76 million shsMarket Capitalization$734.21 millionP/E RatioN/ADividend YieldN/ABeta1.7 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services SectorMedical Current SymbolNASDAQ:PACB Previous Symbol CUSIP69404D10 CIK1299130 Webhttp://www.pacb.com/ Phone650-521-8000Debt Debt-to-Equity Ratio0.84 Current Ratio1.52 Quick Ratio1.22Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$78.63 million Price / Sales9.34 Cash FlowN/A Price / Cash FlowN/A Book Value$0.76 per share Price / Book6.32Profitability EPS (Most Recent Fiscal Year)($0.76) Net Income$-102,560,000.00 Net Margins-139.22% Return on Equity-136.85% Return on Assets-68.30%Miscellaneous Employees401 Outstanding Shares152,960,000Market Cap$734.21 million Next Earnings Date2/6/2020 (Confirmed) OptionableOptionable Receive PACB News and Ratings via Email Sign-up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:PACB Rates by TradingView Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions What is Pacific Biosciences of California's stock symbol? Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB." How were Pacific Biosciences of California's earnings last quarter? Pacific Biosciences of California (NASDAQ:PACB) announced its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by $0.04. The biotechnology company had revenue of $21.92 million for the quarter, compared to the consensus estimate of $28.02 million. Pacific Biosciences of California had a negative return on equity of 136.85% and a negative net margin of 139.22%. View Pacific Biosciences of California's Earnings History. When is Pacific Biosciences of California's next earnings date? Pacific Biosciences of California is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Pacific Biosciences of California. How can I listen to Pacific Biosciences of California's earnings call? Pacific Biosciences of California will be holding an earnings conference call on Thursday, February 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available. What price target have analysts set for PACB? 3 brokerages have issued twelve-month target prices for Pacific Biosciences of California's shares. Their forecasts range from $7.00 to $8.00. On average, they anticipate Pacific Biosciences of California's stock price to reach $7.67 in the next twelve months. This suggests a possible upside of 59.7% from the stock's current price. View Analyst Price Targets for Pacific Biosciences of California. What is the consensus analysts' recommendation for Pacific Biosciences of California? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pacific Biosciences of California. What are Wall Street analysts saying about Pacific Biosciences of California stock? Here are some recent quotes from research analysts about Pacific Biosciences of California stock: 1. According to Zacks Investment Research, "Pacific Biosciences has been gaining ground in the MedTech space on strong Sequel performance. The company’s product revenues also shot up in recent times. Meanwhile, one of Pacific Biosciences’ biggest rival — Illumina — recently announced the termination of the formerly announced $1.20 billion-merger agreement. Per management, Illumina will be paying Pacific Biosciences a termination fee of $98 million. Expansion in gross margin in recent times is also a positive. On the flip side, significant rise in operating expenses remains concerning. The company’s loss per share remained flat year over year. The DNA sequencing market is fraught with competition. The stock has underperformed its industry in a year’s time and is overvalued at the moment." (1/7/2020) 2. Cantor Fitzgerald analysts commented, "We think PACB’s long-read next-generation sequencing platform is the industry standard for deep genomic analysis in human, plant, and animal genomes, as well as RNA. The company has seen mixed revenue performance over the past three years, but we think PACB is getting close to an inflection point, which we think the Street is missing. We see the path to revenue acceleration as multifactorial. These include the launch of its 8 million ZMW SMRT cell, increased penetration of the plant and animal sequencing market, and significant sequencing cost reduction per human genome enabling PACB to become a more mainstream player in human genomics." (5/3/2019) Has Pacific Biosciences of California been receiving favorable news coverage? News stories about PACB stock have trended somewhat positive on Tuesday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Pacific Biosciences of California earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the company's share price in the immediate future. View News Stories for Pacific Biosciences of California. Are investors shorting Pacific Biosciences of California? Pacific Biosciences of California saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 20,380,000 shares, an increase of 7.5% from the December 15th total of 18,960,000 shares. Based on an average daily volume of 2,100,000 shares, the short-interest ratio is currently 9.7 days. Approximately 14.7% of the shares of the stock are sold short. View Pacific Biosciences of California's Current Options Chain. Who are some of Pacific Biosciences of California's key competitors? Some companies that are related to Pacific Biosciences of California include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), BIO-TECHNE (TECH), Bruker (BRKR), Charles River Laboratories Intl. (CRL), Cambrex (CBM), Luminex (LMNX), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE). What other stocks do shareholders of Pacific Biosciences of California own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Illumina (ILMN), FireEye (FEYE), Novavax (NVAX), CenterPoint Energy (CNP), Gilead Sciences (Gild), Netflix (NFLX), Sangamo Therapeutics (SGMO), Pfizer (PFE), Alkaline Water (WTER) and Exelixis (EXEL). Who are Pacific Biosciences of California's key executives? Pacific Biosciences of California's management team includes the folowing people: Dr. Michael W. Hunkapiller, Exec. Chairman, CEO & Pres (Age 70)Ms. Susan K. Barnes, Exec. VP & CFO (Age 65)Mr. James Michael Phillips, Sr. VP of R&D (Age 68)Dr. Stephen Turner, Co-Founder & CTO (Age 51)Dr. Jonas Korlach Ph.D., Chief Scientific Officer Who are Pacific Biosciences of California's major shareholders? Pacific Biosciences of California's stock is owned by a variety of of institutional and retail investors. Top institutional investors include California Public Employees Retirement System (0.21%), Dupont Capital Management Corp (0.16%), Alpine Global Management LLC (0.04%), Ballentine Partners LLC (0.01%) and Havens Advisors LLC (0.01%). Company insiders that own Pacific Biosciences of California stock include James Michael Phillips, Kathy Ordonez, Michael Hunkapiller and Susan K Barnes. View Institutional Ownership Trends for Pacific Biosciences of California. Which institutional investors are selling Pacific Biosciences of California stock? PACB stock was sold by a variety of institutional investors in the last quarter, including Havens Advisors LLC and Alpine Global Management LLC. Company insiders that have sold Pacific Biosciences of California company stock in the last year include James Michael Phillips, Kathy Ordonez, Michael Hunkapiller and Susan K Barnes. View Insider Buying and Selling for Pacific Biosciences of California. Which institutional investors are buying Pacific Biosciences of California stock? PACB stock was acquired by a variety of institutional investors in the last quarter, including Dupont Capital Management Corp, California Public Employees Retirement System and Ballentine Partners LLC. View Insider Buying and Selling for Pacific Biosciences of California. How do I buy shares of Pacific Biosciences of California? Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Pacific Biosciences of California's stock price today? One share of PACB stock can currently be purchased for approximately $4.80. How big of a company is Pacific Biosciences of California? Pacific Biosciences of California has a market capitalization of $734.21 million and generates $78.63 million in revenue each year. The biotechnology company earns $-102,560,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. Pacific Biosciences of California employs 401 workers across the globe.View Additional Information About Pacific Biosciences of California. What is Pacific Biosciences of California's official website? The official website for Pacific Biosciences of California is http://www.pacb.com/. How can I contact Pacific Biosciences of California? Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected] MarketBeat Community Rating for Pacific Biosciences of California (NASDAQ PACB)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 375 (Vote Outperform)Underperform Votes: 320 (Vote Underperform)Total Votes: 695MarketBeat's community ratings are surveys of what our community members think about Pacific Biosciences of California and other stocks. Vote "Outperform" if you believe PACB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PACB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/28/2020 by MarketBeat.com StaffFeatured Article: What are the benefits of a balanced fund?
